NRG Therapeutics

NRG Therapeutics, a pioneering neuroscience company focused on developing novel therapies for severe neurodegenerative conditions, has successfully closed a £50 million Series B funding round. This investment, led by SV Health Investors' Dementia Discovery Fund and including significant backing from the British Business Bank, will propel the company's lead candidate, NRG5051, into human clinical trials for ALS/MND and expand its Parkinson's disease research.

Summary of transaction details:

• Value: £50,000,000
• Sector: Healthcare & Biotech (Neuroscience)
• Advisor: Not mentioned
• Key Entities: Target: NRG Therapeutics; Lead Investor: SV Health Investors' Dementia Discovery Fund; Co-investors: British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures, Omega Funds, Brandon Capital.
• Location: UK (implied)

Note: This Series B funding is crucial for NRG Therapeutics to generate clinical proof of concept for its novel therapies targeting mitochondrial dysfunction, addressing high unmet medical needs in severe neurodegenerative diseases like ALS/MND and Parkinson's.